DK2753346T3 - Ceramidase og celledifferentiering - Google Patents

Ceramidase og celledifferentiering Download PDF

Info

Publication number
DK2753346T3
DK2753346T3 DK12830086.0T DK12830086T DK2753346T3 DK 2753346 T3 DK2753346 T3 DK 2753346T3 DK 12830086 T DK12830086 T DK 12830086T DK 2753346 T3 DK2753346 T3 DK 2753346T3
Authority
DK
Denmark
Prior art keywords
ceramidase
cell differentiation
differentiation
cell
Prior art date
Application number
DK12830086.0T
Other languages
English (en)
Inventor
Edward H Schuchman
Calogera M Simonaro
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Application granted granted Critical
Publication of DK2753346T3 publication Critical patent/DK2753346T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK12830086.0T 2011-09-07 2012-09-07 Ceramidase og celledifferentiering DK2753346T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531917P 2011-09-07 2011-09-07
PCT/US2012/054316 WO2013036875A1 (en) 2011-09-07 2012-09-07 Ceramidase and cell differentiation

Publications (1)

Publication Number Publication Date
DK2753346T3 true DK2753346T3 (da) 2020-05-25

Family

ID=47998559

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12830086.0T DK2753346T3 (da) 2011-09-07 2012-09-07 Ceramidase og celledifferentiering

Country Status (9)

Country Link
US (3) US10350277B2 (da)
EP (2) EP3741384A1 (da)
DK (1) DK2753346T3 (da)
ES (1) ES2791760T3 (da)
HU (1) HUE051021T2 (da)
LT (1) LT2753346T (da)
PL (1) PL2753346T3 (da)
SI (1) SI2753346T1 (da)
WO (1) WO2013036875A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
CN109529028A (zh) 2012-06-01 2019-03-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
ES2802453T3 (es) * 2016-03-24 2021-01-19 Allflex Europe Sa Uso de una composición acuosa para la disolución de biomoléculas de una muestra de tejido
JP2020524515A (ja) * 2017-06-21 2020-08-20 モグリファイ リミテッド 軟骨細胞を産生するための細胞リプログラミング法
EP3813871A4 (en) 2018-06-29 2022-10-12 Icahn School of Medicine at Mount Sinai SPHINGOLIPID METABOLIZING PROTEINS ENCODING FOR ANC80
JP2022514298A (ja) 2018-12-19 2022-02-10 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ オルガノイドおよびその組織を作製および使用するための方法
US20220347276A1 (en) * 2019-09-11 2022-11-03 Icahn School Of Medicine At Mount Sinai Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage
WO2021110908A1 (en) 2019-12-04 2021-06-10 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Device and process for tissue-engineering and regenerative medicine

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585793A5 (da) 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (da) 1974-05-02 1978-07-06
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
IT1130242B (it) 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
EP0897987B1 (en) 1989-10-24 2001-02-28 Chiron Corporation Secretion of human protein linked to gamma interferon signal peptide
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
BR9307800A (pt) 1992-12-30 1995-11-14 George Joe Revis ComposiçÕes anticárie
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
JPH08512056A (ja) 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
DK0787200T3 (da) 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US5871727A (en) 1995-12-08 1999-02-16 Uab Research Foundation Targeted adenovirus vectors
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6066626A (en) 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
CA2323210C (en) 1998-03-10 2013-05-28 The Trustees Of The University Of Pennsylvania Enhancement of intracellular delivery and tissue targeting of drugs and genes
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6258581B1 (en) 1998-08-20 2001-07-10 Takara Shuzo Co., Ltd. Ceramidase gene
ES2187195T3 (es) 1998-09-11 2003-05-16 Gerhard Dr Schmidmaier Implantes biologicamente activos.
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
AU1082701A (en) 1999-10-13 2001-04-23 Yeda Research And Development Co. Ltd. Short segments of dap-kinase
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
IL152110A0 (en) 2000-04-06 2003-07-31 Exegenics Inc Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002051439A2 (en) 2000-12-22 2002-07-04 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1234816B1 (de) 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
US20030109038A1 (en) 2001-12-07 2003-06-12 Thies R. Scott Chondrocyte precursors derived from human embryonic stem cells
BRPI0307074A2 (pt) 2002-01-25 2017-06-20 Genzyme Corp meios sem soro para condrócitos e métodos para seu uso
US20050107868A1 (en) 2002-03-28 2005-05-19 JAPAN as represented by President of NATIONAL & CARDIOVASCULAR CENTER Scaffold for tissue engineering, artificial blood vessel, cuff, and biological implant covering member
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
DE10239531A1 (de) 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
US7220578B2 (en) 2002-11-27 2007-05-22 Tal Kafri Single LTR lentivirus vector
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US20040126405A1 (en) 2002-12-30 2004-07-01 Scimed Life Systems, Inc. Engineered scaffolds for promoting growth of cells
JP5433133B2 (ja) 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
BRPI0412725B8 (pt) 2003-07-17 2021-07-27 Pacific Edge Biotechnology Ltd marcadores para detecção de câncer gástrico
US7897384B2 (en) 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US8017394B2 (en) 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7273756B2 (en) 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8592419B2 (en) 2004-10-29 2013-11-26 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
JP2008537143A (ja) 2005-04-19 2008-09-11 バーミリオン， インコーポレイテッド アルツハイマー病のためのバイオマーカーであるサポシンｄ及びｆａｍ３ｃ
US20070162992A1 (en) 2006-01-09 2007-07-12 Mcgill University Metabolomic determination in assisted reproductive technology
JP2009524829A (ja) 2006-01-27 2009-07-02 イースタン バージニア メディカル スクール ヒトｉｖｆ由来胚のプロテオームフィンガープリンティング：発生能のバイオマーカーの同定法
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
AU2007241622A1 (en) 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
WO2007136635A1 (en) 2006-05-16 2007-11-29 Musc Foundation For Research Development Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
BRPI0713572A2 (pt) 2006-06-20 2012-10-23 Stephen Duguay meios livres de soro e seus usos para expansão de condrócitos
WO2008003320A2 (en) 2006-07-05 2008-01-10 Region Midtjylland Three-dimensional cell scaffolds
AU2008204982A1 (en) * 2007-01-05 2008-07-17 Mount Sinai School Of Medicine Acid ceramidase and cell survival
MX2009010694A (es) 2007-04-06 2009-10-22 Genzyme Corp Metodo para evaluar celulas y cultivos celulares.
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
CN101686996B (zh) 2007-05-31 2012-12-05 格莱肯生物科学公司 硫酸木聚糖在制备用于治疗或预防呼吸疾病的药物的新用途
FR2924946B1 (fr) 2007-12-18 2010-02-26 Oreal Utilisation cosmetique de proteines de type ceramidase acide
DE102007063535A1 (de) 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
RU2011117722A (ru) 2008-11-06 2012-12-20 Фонд Медицинского Университета Южной Каролины по развитию научных исследований Лизосомотропные ингибиторы кислой церамидазы
US20120115158A1 (en) 2009-05-01 2012-05-10 Mount Sinai School Of Medicine Method to determine embryo and oocyte quality based on ceramidase
EP2470199B1 (en) 2009-08-28 2019-05-22 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PT2995306T (pt) 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2012051415A2 (en) 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
WO2013101276A2 (en) 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
CA2833907A1 (en) 2011-05-10 2012-11-15 Advanced Liquid Logic, Inc. Enzyme concentration and assays
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
CN109529028A (zh) 2012-06-01 2019-03-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them

Also Published As

Publication number Publication date
EP2753346B1 (en) 2020-04-22
US20140287015A1 (en) 2014-09-25
SI2753346T1 (sl) 2020-09-30
HUE051021T2 (hu) 2021-01-28
PL2753346T3 (pl) 2020-10-19
WO2013036875A1 (en) 2013-03-14
US10350277B2 (en) 2019-07-16
LT2753346T (lt) 2020-08-10
EP2753346A1 (en) 2014-07-16
US20190321454A1 (en) 2019-10-24
EP2753346A4 (en) 2015-08-12
US20250018017A1 (en) 2025-01-16
ES2791760T3 (es) 2020-11-05
EP3741384A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
PT2730564T (pt) Aminas heterocíclicas e suas utilizações
DK2855736T3 (da) Elektrolysator og energisystem
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK3346008T3 (da) Rekombinante mikroorganismer og anvendelser deraf
DK2837680T3 (da) Mammaliacellekultur
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
EP2788470A4 (en) CLOSED BIOREACTORS
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112012027159A2 (pt) estrutura e método
SG11201400484RA (en) Novel heterocyclic derivatives and their uses
EP2664261A4 (en) MILL
EP2879794A4 (en) CELL CULTURE
EP2753346A4 (en) CERAMIDASE AND CELL DIFFERENTIATION
DK2921493T3 (da) Heteroarylpiperidin og ¿piperazinderivater
DK3392252T3 (da) Pyrimido-pyridazinonforbindelser og deres anvendelse
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
BR112013009579A2 (pt) método e comprimido
PL3763468T3 (pl) Frez
EP2662144A4 (en) MILL
CO6940387A2 (es) Aparato y método de chancado
HRP20200794T1 (hr) Keramidaza i diferencijacija stanica
DK2723873T4 (da) P0-gen-nedreguleringskonstruktioner og anvendelse deraf